Shopping Cart 0
Cart Subtotal
AED 0

Portola Pharmaceuticals Inc (PTLA) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

Portola Pharmaceuticals Inc (PTLA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company that conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc Key Recent Developments

Aug 07,2019: Portola Pharmaceuticals reports second quarter 2019 financial results and provides corporate update

May 08,2019: Portola Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Apr 24,2019: Portola Pharmaceuticals announces retirement of Dr. John Curnutte, executive vice president and head of research and development

Mar 20,2019: Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors

Mar 20,2019: Portola Pharmaceuticals Co-Founder Dr. Charles Homcy retires from the company's Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Portola Pharmaceuticals Inc-Key Facts

Portola Pharmaceuticals Inc-Key Employees

Portola Pharmaceuticals Inc-Key Employee Biographies

Portola Pharmaceuticals Inc-Major Products and Services

Portola Pharmaceuticals Inc-History

Portola Pharmaceuticals Inc-Company Statement

Portola Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Portola Pharmaceuticals Inc-Business Description

R&D Overview

Portola Pharmaceuticals Inc-SWOT Analysis

SWOT Analysis-Overview

Portola Pharmaceuticals Inc-Strengths

Portola Pharmaceuticals Inc-Weaknesses

Portola Pharmaceuticals Inc-Opportunities

Portola Pharmaceuticals Inc-Threats

Portola Pharmaceuticals Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Aug 07, 2019: Portola Pharmaceuticals reports second quarter 2019 financial results and provides corporate update

May 08, 2019: Portola Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Apr 24, 2019: Portola Pharmaceuticals announces retirement of Dr. John Curnutte, executive vice president and head of research and development

Mar 20, 2019: Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors

Mar 20, 2019: Portola Pharmaceuticals Co-Founder Dr. Charles Homcy retires from the company's Board of Directors

Mar 01, 2019: Portola Pharmaceuticals reports fourth quarter and full year 2018 financial results and provides corporate update

Mar 01, 2019: Portola Pharmaceuticals enters into USD 125 million loan agreement with HealthCare Royalty Partners and Athyrium Capital Management

Jan 28, 2019: Portola Pharmaceuticals names Sheldon Koenig as Chief Commercial Officer

Jan 24, 2019: Lonza to commence commercial supply of Portolas second-generation Andexxa

Nov 07, 2018: Portola Pharmaceuticals reports third quarter 2018 financial results and provides corporate update

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Portola Pharmaceuticals Inc, Performance Chart (2014-2018)

Portola Pharmaceuticals Inc, Ratio Charts

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Portola Pharmaceuticals Inc, Key Facts

Portola Pharmaceuticals Inc, Key Employees

Portola Pharmaceuticals Inc, Key Employee Biographies

Portola Pharmaceuticals Inc, Major Products and Services

Portola Pharmaceuticals Inc, History

Portola Pharmaceuticals Inc, Subsidiaries

Portola Pharmaceuticals Inc, Key Competitors

Portola Pharmaceuticals Inc, Ratios based on current share price

Portola Pharmaceuticals Inc, Annual Ratios

Portola Pharmaceuticals Inc, Annual Ratios (Cont...1)

Portola Pharmaceuticals Inc, Interim Ratios

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Portola Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Xencor Inc

SELLAS Life Sciences Group Inc

Inotek Pharmaceuticals Corp

KemPharm Inc

Company Profile

Company Profile Title

Portola Pharmaceuticals Inc (PTLA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company that conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc Key Recent Developments

Aug 07,2019: Portola Pharmaceuticals reports second quarter 2019 financial results and provides corporate update

May 08,2019: Portola Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Apr 24,2019: Portola Pharmaceuticals announces retirement of Dr. John Curnutte, executive vice president and head of research and development

Mar 20,2019: Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors

Mar 20,2019: Portola Pharmaceuticals Co-Founder Dr. Charles Homcy retires from the company's Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Portola Pharmaceuticals Inc-Key Facts

Portola Pharmaceuticals Inc-Key Employees

Portola Pharmaceuticals Inc-Key Employee Biographies

Portola Pharmaceuticals Inc-Major Products and Services

Portola Pharmaceuticals Inc-History

Portola Pharmaceuticals Inc-Company Statement

Portola Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Portola Pharmaceuticals Inc-Business Description

R&D Overview

Portola Pharmaceuticals Inc-SWOT Analysis

SWOT Analysis-Overview

Portola Pharmaceuticals Inc-Strengths

Portola Pharmaceuticals Inc-Weaknesses

Portola Pharmaceuticals Inc-Opportunities

Portola Pharmaceuticals Inc-Threats

Portola Pharmaceuticals Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Aug 07, 2019: Portola Pharmaceuticals reports second quarter 2019 financial results and provides corporate update

May 08, 2019: Portola Pharmaceuticals reports first quarter 2019 financial results and provides corporate update

Apr 24, 2019: Portola Pharmaceuticals announces retirement of Dr. John Curnutte, executive vice president and head of research and development

Mar 20, 2019: Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors

Mar 20, 2019: Portola Pharmaceuticals Co-Founder Dr. Charles Homcy retires from the company's Board of Directors

Mar 01, 2019: Portola Pharmaceuticals reports fourth quarter and full year 2018 financial results and provides corporate update

Mar 01, 2019: Portola Pharmaceuticals enters into USD 125 million loan agreement with HealthCare Royalty Partners and Athyrium Capital Management

Jan 28, 2019: Portola Pharmaceuticals names Sheldon Koenig as Chief Commercial Officer

Jan 24, 2019: Lonza to commence commercial supply of Portolas second-generation Andexxa

Nov 07, 2018: Portola Pharmaceuticals reports third quarter 2018 financial results and provides corporate update

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Portola Pharmaceuticals Inc, Performance Chart (2014-2018)

Portola Pharmaceuticals Inc, Ratio Charts

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Portola Pharmaceuticals Inc, Key Facts

Portola Pharmaceuticals Inc, Key Employees

Portola Pharmaceuticals Inc, Key Employee Biographies

Portola Pharmaceuticals Inc, Major Products and Services

Portola Pharmaceuticals Inc, History

Portola Pharmaceuticals Inc, Subsidiaries

Portola Pharmaceuticals Inc, Key Competitors

Portola Pharmaceuticals Inc, Ratios based on current share price

Portola Pharmaceuticals Inc, Annual Ratios

Portola Pharmaceuticals Inc, Annual Ratios (Cont...1)

Portola Pharmaceuticals Inc, Interim Ratios

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Portola Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Portola Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Xencor Inc

SELLAS Life Sciences Group Inc

Inotek Pharmaceuticals Corp

KemPharm Inc